Lupin Ltd. Receives VAI Status from U.S. FDA for Aurangabad Manufacturing Facility

Global pharma major Lupin Ltd. has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Aurangabad manufacturing facility. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). Nilesh Gupta, Managing Director of Lupin, expressed pleasure at this development, stating that it's a testament to Lupin's commitment to compliance and quality. Lupin is the third-largest pharmaceutical company in the U.S., has a significant presence in various therapeutic areas, and is headquartered in Mumbai, India. The company generated revenue of 7.9% for research and development in FY23.